Authors
Mukherjee, D., Ghosh, P., Rajmani, R. S., Verma, K., Gowda, A., Birua, A., Rao, L., Chakravortty, D.
Abstract
Surgical site infections are among the most prevalent postoperative complications and remain a pressing global health challenge, exacerbated by the rise of antimicrobial resistance. Plasma activated water (PAW) has recently gained attention as an innovative antimicrobial approach. However, earlier research indicated that its effectiveness relies on maintaining an acidic pH. To address this, we previously created a high-strength, neutral pH buffered version (hs PAbW) that is better suited for clinical use in humans. This neutral plasma activated water retained the potent antimicrobial activity. In this study, we engineered a hydrogel containing hs-PAbW at a bactericidal yet non-cytotoxic dose (hs PAbW 20) and assessed its efficacy in murine wound models. In Balb/c mice, hs PAbW 20 gel significantly reduced Pseudomonas aeruginosa and Staphylococcus aureus burden, achieving results comparable to neomycin and soframycin treatments. This gel also accelerated wound closure by modulating genes crucial for wound repair. In diabetic C57BL/6 mouse model, hs PAbW 20 gel decreased the burden of P. aeruginosa and promoted faster healing. Together, these findings establish hs PAbW 20 gel as a promising next generation therapeutic with the potential to overcome limitations of conventional antibiotic-based wound care.
Preprint server:
bioRxiv
The authors list and abstract were imported from bioRxiv on 12 Nov 2025.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 28
- Comments 0